On June 20, Gelon Hui reported that Kolanibotai Biology-B (06990.HK) announced that the company's board of directors has reviewed and approved the proposed implementation of full circulation of shares held by certain shareholders of the company, which accounts for no more than 0.52% of the total share capital of the company as of the announcement date.

As of the announcement date, all H shares will need to obtain all relevant approvals (including the filing notice of the China Securities Regulatory Commission), convert such shares into H shares of the company (and the Listing Committee of the Hong Kong Stock Exchange approves H shares to be listed and traded on the main board of the Hong Kong Stock Exchange).